PROTACs vs. Molecular Glues: Comparing Targeted Protein Degraders for Size and Permeability in Drug Selection

August 30, 2026

Drug Target Review UK

Overview

PROTACs and molecular glues represent two distinct strategies for targeted protein degradation, each with unique advantages and challenges. PROTACs are bifunctional molecules that recruit an E3 ligase to a target protein for degradation but face issues with larger size, cell permeability, and oral bioavailability. Molecular glues, on the other hand, are single small molecules that induce or stabilize novel interactions between a target protein and an E3 ligase, offering better drug-like properties, cell access, and potential for oral administration due to their smaller size.

In Depth

Key Findings

Targeted Protein Degradation (TPD) has emerged as a revolutionary drug discovery modality, offering the ability to target previously ‘undruggable’ proteins that conventional inhibitors could not address. Within this field, PROTACs (Proteolysis-Targeting Chimeras) and molecular glues are the two primary strategies. Each possesses distinct mechanisms and properties, making the selection of the appropriate approach critical depending on the target protein characteristics and therapeutic goals.

Technical & Clinical Details

PROTACs Mechanism and Properties:
- Bifunctional Molecules: PROTACs are designed as bifunctional molecules, comprising a ligand that binds to the target protein and another ligand that binds to an E3 ubiquitin ligase, connected by a chemical linker.
- Mechanism of Action: By simultaneously engaging both the target protein and the E3 ligase, PROTACs induce ubiquitination of the target, leading to its degradation via the proteasome pathway.
- Advantages: Unlike enzyme inhibitors, PROTACs act catalytically, meaning they can achieve significant target degradation at low concentrations and are particularly effective when a known ligand for the target protein exists.
- Challenges: A primary limitation of PROTACs is their relatively large molecular size, which can impede cell membrane permeability and intracellular access, often making their development as oral drugs challenging.
Molecular Glues Mechanism and Properties:
- Single Small Molecules: In contrast to PROTACs, molecular glues are single, small-molecule compounds.
- Mechanism of Action: They induce or stabilize novel interactions between a target protein and an E3 ligase that would not ordinarily occur, leading to ubiquitination and degradation. A classic example is thalidomide’s interaction with cereblon to induce degradation of proteins like GSPT1.
- Advantages: Due to their smaller size, molecular glues typically possess more favorable drug-like properties, including better cell membrane permeability and enhanced intracellular access, making them promising candidates for oral administration. They also offer the potential to discover new degradation pathways even in the absence of known target ligands.
- Challenges: The discovery of molecular glues often relies on serendipitous screening and can be less predictable than PROTAC design. Their complex mechanisms of action also require careful consideration of potential off-target effects.

Background & Context

Traditional drug discovery primarily focused on small molecules that inhibit protein active sites, leaving approximately 80% of the proteome ‘undruggable.’ Targeted protein degradation technologies offer a revolutionary paradigm shift by inducing the complete removal of disease-causing proteins rather than merely inhibiting their activity. This approach has the potential to overcome the limitations of conventional drug discovery, paving the way for novel therapies for intractable diseases.

Strategic Significance & Outlook

Both PROTACs and molecular glues are rapidly evolving fields, with intensive research focused on overcoming their respective technical challenges. PROTACs offer broader target scope, while molecular glues excel in drug-like properties and access to unexplored targets. Future developments may include hybrid strategies combining aspects of both, or entirely new modalities that leverage their strengths. These protein degraders are expected to drive a therapeutic paradigm shift not only in cancer treatment but also in neurodegenerative disorders, autoimmune diseases, and other areas with significant unmet medical needs.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.